DHTKD1 and glioma: To enhance the potency and reduce the toxicity of adenovirus vectors the replication of HAdV-5 vectors for glioma therapy has been restricted by using promoters that are preferentially expressed in tumor cells for driving expression of key viral genes such as E1A.